Chronic Pain Program
Chronic pain affects an estimated 1.5 billion individuals worldwide and is one of the hardest conditions to treat. More than 11 million Americans last year turned to off-label use of medications to treat their chronic pain. This type of medication provides relief for only a short period of time and can put patients at risk of complications.
Our chronic pain product candidate, EP-104EPI, is a non-opioid, locally administered, sustained release compound that aims to provide extended pain relief while reducing potential complications. Our first target is back pain – one of the most prevalent areas requiring chronic pain medication.